Company Ventures

Company Ventures Research Investment Thesis Company Ventures operates one of the only large-scale, no-equity, free-rent founder residencies embedded directly inside a 1M+ sq ft Manhattan tech campus (Grand Central Tech). The firm believes that providing capital, community, and operational support to early-stage founders creates a powerful platform for identifying and nurturing the next generation of category-defining companies. Their unique thesis is that by offering founders space, mentorship, and access to the Company Ventures network—without taking equity—they can build deep relationships and identify the strongest founders before traditional institutional investors find them. History and Evolution Company Ventures traces its roots to Grand Central Tech, founded in 2014 by Matt Harrigan and Charles Bonello as a founder residency program in a 15,000 sq ft space on Madison Avenue. The program grew to occupy a 1M+ sq ft innovation campus in midtown Manhattan. In 2018, the venture investing arm (Company Ventures) formalized and began making equity investments alongside the residency program. Today, the firm operates as an integrated platform combining: Grand Central Tech Residency (zero-equity, zero-rent) Venture investing (typically $250K investments at pre-seed and seed) Terrarium (new venture studio focused on healthcare) Boost founder fellowship program City Fellowship for impact-oriented entrepreneurs Investment Model Grand Central Tech Residency (Core Program) Duration: One year, no rent, zero equity Support: Private office space (30-100 sq ft), administrative support, community access Portfolio: 380+ companies supported across 13 cohorts (as of Spring 2025) Alumni performance: $1.9B+ raised by GCT cohort companies from institutional investors Founder base: Attracts NYC's premier early-stage founders Venture Investment Arm Typical check size: $250,000 (often as conclusion of residency) Stage focus: Pre-seed and seed Investment criteria: Strong founders, viable business model, alignment with GCT support Most investments come from residency program graduates Fund II (Seed VC - II) actively deploying with 53+ total investments Stage Focus Company Ventures focuses exclusively on early-stage investments: Pre-seed: $250K for concept/prototype validation Seed: $250K-$1.5M for MVP with initial traction Occasionally co-invest in Series A follow-ons for portfolio companies The firm specializes in being the first institutional investor for many founders, giving them pattern recognition advantage in founder quality. Check Size and Investment Activity Typical investment range: $250,000 - $1,500,000 Most investments: $250K standard check Co-investment opportunities: Up to $1.5M with partners Fund size: Seed VC - II with 53+ portfolio companies as of June 2025 Recent activity: Juniper Genomics ($4.6M seed led, June 2025), active deployment throughout 2025 Portfolio Composition and Recent Activity Notable Portfolio Companies: Robinhood (unicorn, fintech) Maven (unicorn, healthcare) Illumio (unicorn, cybersecurity) Republic (equity crowdfunding platform) Juniper Genomics (genomics/reproductive health, $4.6M seed, June 2025) MikMak (business software) Formulary Financial (financial software) Cohesive AI (AI) Sector Diversity: Unlike specialist VCs, Company Ventures maintains a generalist approach with exposure to: Fintech and payments (Robinhood) Healthcare and biotech (Maven, Juniper Genomics) Cybersecurity (Illumio) Platforms and tools (Republic, MikMak) AI/ML (Cohesive AI) Consumer and enterprise software Recent Activity (2025): Juniper Genomics: Led $4.6M seed round (June 2025) for IVF genomics startup Spring 2025 Cohort: Accepted new class of founders into Grand Central Tech Terrarium Launch: New healthcare-focused venture studio (February 2025) Continued active deployment from Seed VC - II fund Team and Culture Leadership: Matt Harrigan, CEO & Managing Partner - Co-founder of Grand Central Tech (2014), drove evolution into venture investing, Brooklyn native, deeply committed to NYC tech ecosystem Nelson Boone Schubart, Managing Partner - NYC-based, focuses on founder support and community building Michael Milstein, Partner - Investment focus Support Team: Julia Grassa, Head of Talent - Recruiting and founder services Tara Kaess, Talent Principal - Recent addition for expanded talent operations The team is known for deep founder relationships, hands-on mentorship, and commitment to NYC as a tech hub. Geographic and Market Focus Primary Market: New York City and tristate area Anchored to 1M+ sq ft campus in Manhattan Direct access to NYC founder ecosystem Strong network of NYC-based founders and operators Secondary Market: National reach Founders relocate to NYC for GCT program National recruitment for residency Portfolio companies based throughout US International: Selective, primarily US-focused Juniper Genomics is Toronto-based (Canadian) Primarily domestic strategy Investment Criteria and Founder Preferences Who They Back: Founders with deep domain expertise or technical capability Teams committed to building category-defining companies Founders willing to relocate to NYC for residency (optional but encouraged) First-time founders and repeat founders equally valued Diverse backgrounds and perspectives Anti-Thesis: Late-stage growth capital (they exit before Series B) Companies not aligned with residency program values Fully remote-first companies (residency is office-based) Competitive Positioning Differentiation: Operational leverage: The residency provides real estate, community, and support—not just capital Pattern recognition: Access to 380+ founders gives them market insight most VCs lack NYC focus: Deep local network in underinvested market relative to SF/Boston Founder first: Zero-equity residency positions them as founder advocates, not extractive Community: GCT creates ongoing founder network with $1.9B in aggregate institutional funding Competitive Set: Techstars (different model—accelerator with equity) Lerer Hippeau (NYC competitor, more traditional VC) Greycroft (NYC competitor) Plug and Play (different model—acceleration) Decision Process and Investment Thesis How They Decide: Partnership model with consensus among partners Strong founder signals from residency program Quick decision timeline (typically 2-4 weeks) Co-investment with other early investors Warm Introductions: Preferred but not required for residency program applications Strongly encouraged for direct venture investment Existing founder network provides most deal flow Recent Initiatives Terrarium (2025): New venture studio for healthcare founders, addressing gap in founder capital and support for life sciences entrepreneurs. Boost Fellowship (2024+): Founder fellowship program separate from residency, for operational founders in early cohorts. City Fellowship: Ongoing initiative supporting impact-oriented, tech-enabled nonprofits and small businesses. Exit Activity and Fund Dynamics Based on available data: Active investor with continuous deployment Seed VC - II fund in active deployment phase 53+ total investments across portfolio Focus on supporting founders through early exits, acquisitions, and continuation to Series A Strong network of downstream investors (Series A firms actively backing GCT alumni) Market Position and Reputation Company Ventures is recognized as: NYC Tech Advocate: Strong voice for New York tech ecosystem, founder champion Early-stage specialist: Consistent focus on pre-seed and seed Founder-friendly: No-equity residency positions them well with founder community Pattern recognizer: Track record of backing companies that went on to raise from top-tier Series A investors Community builder: GCT alumni network provides ongoing founder support and company-to-company introductions Geographic and Demographic Trends Company Ventures' recent activities suggest: Continued focus on healthcare innovation (Juniper Genomics, Terrarium studio) Expansion beyond traditional tech into deep tech (reproductive health, genomics) Commitment to NYC as long-term base despite national spread of startups Interest in founder support infrastructure (Boost, City Fellowship) alongside direct investing Assessment Summary Company Ventures operates a unique model combining founder residency with early-stage venture investing. Their competitive advantage stems from: Direct access to high-quality founder pool through residency Hands-on operational support beyond capital Strong NYC network and ecosystem position Founder-friendly reputation (zero-equity residency) Emerging track record of backing strong companies (Robinhood, Maven, Illumio) Their focus on pre-seed and seed, combined with residency support, makes them ideal for founders seeking operational mentorship alongside capital. The firm is best suited for founders willing to relocate to NYC and looking for hands-on investor partners.